1559
Hospital Authority. “Monitoring for hepatotoxicity during antituberculosis treatment,” Hong Kong. April
2002. (Hong Kong 2002)
American Thoracic Society/Centers of Disease Control and Prevention/Infectious Disease Society of America.
(2006), “An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy,”
Am.J.Respir.Crit.Care
Med.
174, 935-952.
American Thoracic Society, CDC, and Infectious Diseases Society of America. (2003). “Treatment of
Tuberculosis,”
MMWR
. 52, RR11.
Bini, E.J. and Perumalswami , P.V. (2010). “Hepatitis B virus infection among American patients with chronic
hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions,”
Hepatology
. 51(3),
759-66.
Cummings, S.M., Savitz, L.A. and Konrad, T.R. (2001). “Reportd Response Rates to Mailed Physician
Questionnaires,”
Health Serv Res.
5(6), 1347-55.
Durand, F., Jebrak ,G., Pessayre, D., Fournier, M. and Bernuau, J. (1996). “Hepatotoxicity of Antitubercular
Treatments Rationale for Monitoring Liver Satus,”
Drug Safety.
vol 15(6), 394-405.
Forget, E.J. and Menzies, D. (2006). “Adverse reactions to first-line antituberculosis drugs,”
Expert Opin. Drug
Saf.
5(2), 231-249.
Grosset, J. and Leventis, S. (1983). “Adverse Effects of Rifampicin,”
Reviews of infectious diseases.
5(3), s440-
s450.
Joint Tuberculosis Committee of the Bristish Thoracic Society. (1998). “Chemotherapy and management of
tuberculosis in the United Kingdom: recommendations 1998,”
Thorax.
53, 536-548.
Liang, S.H., Chen, T.J., Lee, S.S., Tseng, F.C., Huang, C.K., Lai. C.H. and Chiou, C.P. (2010). “Risk factors of
isolated antibody against core antigen of hepatitis B virus: association with HIV infection and age but not
hepatitis C virus infection,”
J Acquir Immune Defic Syndr.
54(2), 122-128.
Mohi-ud-din, R. and Lewis, J.H. (2004). “Drug- and chemical-induced cholestasis,”
Clin Liver Dis.
8, 95-132.
Navarro, V. and Senior, J.R. (2006). “Drug-Related Hepatotoxicity,”
N Engl J Med.
354, 731-739.
Sharma, S.K., Balamurugan, A., Saha, P.K., Pandey, R.M. and Mehra N.K. (2002). “Evaluation of Clinical and
Immunogenetic Risk Factors for the Development of Hepatotoxicity during Antituberculosis Treatment,”
Am
J Respir Crit Care Med.
166, 916–919.
Steele, M.A., Burk, R.F. and DesPrez, R.M. (1991). “Toxic Hepatitis with Isoniazid and Rifampicin A Meta-
Analysis,”
Chest.
99, 465-471.
Teleman, M.D., Chee, C.B.E., Earnest, A. and Wang, Y.T. (2002). “Hepatotoxicity of tuberculosis chemotherapy
under general programme conditions in Singapore,”
Int J Terberc Lung Dis.
6(8), 699-705.
World Health Organization report (2009).
Global tuberculosis control: surveillance, planning, financing.
Accessed: 22 June 2009, Aviailable
Geneva, Switzerland: WHO, 2009.
World Health Organization. (2003).
Treatment of tuberculosis: guidelines for national programmes.
